Product Reports Resources Pricing Login Book a demo

uMotif

Biotech & Life Sciences · London, United Kingdom · Founded 2012

Patient-centric eClinical platform for decentralized research data MoreLess

uMotif is a London-based digital health company that offers a patient-centric data capture platform for clinical research. Founded in 2012 by Bruce Hellman and Ben James, the company's mission is to place patients at the heart of clinical studies. The idea was sparked after the co-founders met with two Parkinson's Disease patients who wanted digital tools to better track and understand their condition and healthcare journey. Co-founder Bruce Hellman has a background in clinical trials and an MBA from Imperial College, which provided a strong foundation in business and the importance of user-centric design.

The company provides a software-as-a-service (SaaS) application that enables patients to track their health and self-reported outcomes through a mobile app. This cloud-native platform is designed for pharmaceutical companies, biotechs, contract research organizations (CROs), and academic institutions. It captures regulatory-compliant data such as eConsent, electronic Clinical Outcome Assessments (eCOA), and Patient-Reported Outcomes (ePRO), as well as data from wearable devices. The business model serves clients like AstraZeneca, Abbvie, and Syneos, helping them achieve high rates of data capture (in excess of 90%), improve patient retention, and accelerate research timelines. By focusing on a user-friendly experience, the platform aims to reduce the burden on study participants, leading to higher compliance and data quality.

uMotif's platform supports various study designs, from traditional site-based trials to fully decentralized and post-marketing research. Its solutions include Trial Awareness and Patient Ride with Uber Health to bolster the patient-site relationship. The company has raised a total of $35.4 million over six funding rounds, with its latest Series B round in May 2022 securing $25.5 million, led by Athyrium Capital Management. This funding supports international expansion, particularly in North America, and further platform development.

Keywords: patient-centric data, eClinical platform, clinical research, real-world studies, eCOA, ePRO, decentralized trials, patient engagement, patient-reported outcomes, data capture, health self-management, eConsent, clinical trials software, MedTech, life sciences technology, digital health, symptom tracking, wearable device data, site productivity tools, remote data collection

Valuation $100–500M
Revenue $10–50M
Headcount <100
Total funding $10–50M
Unlock exact values This page shows ranges. Dealroom has the exact numbers for uMotif and the history behind them.

Company overview

uMotif company information

The essential company record, classifications and operating signals in one place.

Status
Operational
Founded
2012
Headquarters
London, United Kingdom
Employees
99
Open positions
None listed
Dealroom signal
79.7
client focusb2csub industryBioTechnologysub industryHealth Platformbusiness modelSaaSindustryHealthsectorBiotechnologysectorTech for Biotech and PharmasectorAI Drug DiscoverysectorTechbiosectorHard TechsectorTechbio Drug DiscoverysectorDigital PharmasectorDT and LSsectoruk is8 digital and technologies

Valuation & funding

uMotif funding history

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES BEquity / VC May 2022 $26M $102M DNV · AlbionVC · Athyrium Capital Management
SERIES AEquity / VC Sep 2020 $7.9M $32M AlbionVC
EARLY VCEquity / VC Jun 2018 $3.2M $13M AlbionVC
GRANTOther financing Sep 2016 $119K SBRI Healthcare
GRANTOther financing Sep 2014 $132K SBRI Healthcare
GRANTOther financing Sep 2013 SBRI Healthcare
GRANTOther financing Mar 2012 SBRI Healthcare
Showing 7 recorded eventsUnlock the complete deal history →

Financials

Revenue and workforce over time

Available revenue and workforce history. Fields without reported data are omitted.

YearRevenueGrowthEmployees
2026 $16M 0% 101
2025 $16M 0% 92
2024 $16M 0% 95
2023 $16M 0% 112
2022 $16M +71.9%
2021 $9.3M +39.7%
2020 $6.6M
Company filings, research estimates and Dealroom dataOpen the full financial model →

Growth signals

uMotif website traffic

Latest recorded traffic for uMotif is 3.7K monthly website visits, down 27.5% over the last three months. uMotif's team grew 7.6% over the past year.

Latest monthly visits3.7K 3-month web change-27.5% 1-year team growth+7.6%
Monthly website visits141 observations · Oct 2014–Jul 2026
Hover or focus a point to see its exact monthly valueCompare with peers →

Comparisons

uMotif compared with similar companies

Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.

Showing 8 of the closest matchesCompare every metric →

Talent graph

uMotif's talent

Book a demo to see the people
Team profiled 18 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 11 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

5 investors on uMotif's cap table

Sourced from Dealroom's funding and investor records.

Seed 1 investor entered at this stage
SBRI Healthcare
Series A 3 investors entered at this stage
AlbionVC
Athyrium Capital Management
DNV
Other known 1 additional known investor
Alastair Mitchell

Global footprint

Where uMotif has talent and traffic

Workforce by country
3 countries with
team presence
🇬🇧 United Kingdom59.2%
🇺🇸 United States39.5%
🇮🇪 Ireland1.3%
3 countries shown

In the news

Latest news about uMotif

Recent press, funding announcements, and product moves mentioning uMotif — open to read from the original sources.

See all news

Market sentiment

What the market is saying about uMotif

An AI-synthesized read of the highest-engagement posts about uMotif on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See uMotif’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.